HN 11500

Known as: HN-11500, HN11500 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1992-2008
01219922008

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
  • 2008
The development of echo contrast agents that can provide reliable opacification of the myocardium after intravenous injection is… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1994
1994
In the present study we have investigated the effect of a 100 mg single oral dose of a newly developed thromboxane A2 receptor… (More)
Is this relevant?
1994
1994
The effect of thromboxane receptor antagonist HN 11500 (Chemie Linz AG, Austria) on thrombus formation in laser thrombosis model… (More)
Is this relevant?
1993
1993
Molsidomin is a vasodilating drug and a specific activator of the endothelium-derived relaxing factor (EDRF). Molsidomin has been… (More)
Is this relevant?
1992
1992
Intravenous injection of the ultrasound contrast agent Albunex (manufactured by Nycomed AS, Oslo, Norway; 400 million air-filled… (More)
Is this relevant?